Nationwide Outcome after Pancreatoduodenectomy in Patients at very High Risk (ISGPS-D) for Postoperative Pancreatic Fistula.


Journal

Annals of surgery
ISSN: 1528-1140
Titre abrégé: Ann Surg
Pays: United States
ID NLM: 0372354

Informations de publication

Date de publication:
11 Dec 2023
Historique:
medline: 11 12 2023
pubmed: 11 12 2023
entrez: 11 12 2023
Statut: aheadofprint

Résumé

To assess nationwide surgical outcome after pancreatoduodenectomy (PD) in patients at very high risk for postoperative pancreatic fistula (POPF), categorized as ISGPS-D. Morbidity and mortality after ISGPS-D PD is perceived so high that a recent randomized trial advocated prophylactic total pancreatectomy (TP) as alternative aiming to lower this risk. However, current outcomes of ISGPS-D PD remain unknown as large nationwide series are lacking. Nationwide retrospective analysis including consecutive patients undergoing ISGPS-D PD (i.e., soft texture and pancreatic duct ≤3 mm), using the mandatory Dutch Pancreatic Cancer Audit (2014-2021). Primary outcome was in-hospital mortality and secondary outcomes included major morbidity (i.e., Clavien-Dindo grade ≥IIIa) and POPF (ISGPS grade B/C). The use of prophylactic TP to avoid POPF during the study period was assessed. Overall, 1402 patients were included. In-hospital mortality was 4.1% (n=57), which decreased to 3.7% (n=20/536) in the last 2 years. Major morbidity occurred in 642 patients (45.9%) and POPF in 410 (30.0%), which corresponded with failure to rescue in 8.9% (n=57/642). Patients with POPF had increased rates of major morbidity (88.0% vs. 28.3%; P<0.001) and mortality (6.3% vs. 3.5%; P=0.016), compared to patients without POPF. Among 190 patients undergoing TP, prophylactic TP to prevent POPF was performed in 4 (2.1%). This nationwide series found a 4.1% in-hospital mortality after ISGPS-D PD with 45.9% major morbidity, leaving little room for improvement through prophylactic TP. Nevertheless, given the outcomes in 30% of patients who develop POPF, future randomized trials should aim to prevent and mitigate POPF in this high-risk category.

Sections du résumé

OBJECTIVE OBJECTIVE
To assess nationwide surgical outcome after pancreatoduodenectomy (PD) in patients at very high risk for postoperative pancreatic fistula (POPF), categorized as ISGPS-D.
SUMMARY BACKGROUND DATA BACKGROUND
Morbidity and mortality after ISGPS-D PD is perceived so high that a recent randomized trial advocated prophylactic total pancreatectomy (TP) as alternative aiming to lower this risk. However, current outcomes of ISGPS-D PD remain unknown as large nationwide series are lacking.
METHODS METHODS
Nationwide retrospective analysis including consecutive patients undergoing ISGPS-D PD (i.e., soft texture and pancreatic duct ≤3 mm), using the mandatory Dutch Pancreatic Cancer Audit (2014-2021). Primary outcome was in-hospital mortality and secondary outcomes included major morbidity (i.e., Clavien-Dindo grade ≥IIIa) and POPF (ISGPS grade B/C). The use of prophylactic TP to avoid POPF during the study period was assessed.
RESULTS RESULTS
Overall, 1402 patients were included. In-hospital mortality was 4.1% (n=57), which decreased to 3.7% (n=20/536) in the last 2 years. Major morbidity occurred in 642 patients (45.9%) and POPF in 410 (30.0%), which corresponded with failure to rescue in 8.9% (n=57/642). Patients with POPF had increased rates of major morbidity (88.0% vs. 28.3%; P<0.001) and mortality (6.3% vs. 3.5%; P=0.016), compared to patients without POPF. Among 190 patients undergoing TP, prophylactic TP to prevent POPF was performed in 4 (2.1%).
CONCLUSION CONCLUSIONS
This nationwide series found a 4.1% in-hospital mortality after ISGPS-D PD with 45.9% major morbidity, leaving little room for improvement through prophylactic TP. Nevertheless, given the outcomes in 30% of patients who develop POPF, future randomized trials should aim to prevent and mitigate POPF in this high-risk category.

Identifiants

pubmed: 38073575
doi: 10.1097/SLA.0000000000006174
pii: 00000658-990000000-00717
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.

Auteurs

Rutger T Theijse (RT)

Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands.
Cancer Center Amsterdam, Amsterdam, the Netherlands.

Thomas F Stoop (TF)

Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands.
Cancer Center Amsterdam, Amsterdam, the Netherlands.
Division of Surgical Oncology, Department of Surgery, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA.

Tessa E Hendriks (TE)

Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands.
Cancer Center Amsterdam, Amsterdam, the Netherlands.
Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands.

J Annelie Suurmeijer (JA)

Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands.
Cancer Center Amsterdam, Amsterdam, the Netherlands.

F Jasmijn Smits (FJ)

Department of Surgery, Regional Academic Cancer Center Utrecht, University Medical Center Utrecht and St. Antonius Hospital Nieuwegein, Utrecht University, the Netherlands.

Bert A Bonsing (BA)

Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands.

Daan J Lips (DJ)

Department of Surgery, Medisch Spectrum Twente, Enschede, the Netherlands.

Eric Manusama (E)

Department of Surgery, Medisch Centrum Leeuwarden, the Netherlands.

Erwin van der Harst (E)

Department of Surgery, Maasstad Hospital, Rotterdam, the Netherlands.

Gijs A Patijn (GA)

Department of Surgery, Isala Clinics, Zwolle, the Netherlands.

Jan H Wijsman (JH)

Department of Surgery, Amphia Hospital, Breda, the Netherlands.

Mark Meerdink (M)

Department of Surgery, University Medical Center Groningen, Groningen, the Netherlands.

Marcel den Dulk (M)

Department of Surgery, Maastricht University Medical Center, Maastricht, the Netherlands.
Department of General, Visceral and Transplant Surgery, University Hospital Aachen, Germany.
NUTRIM-School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, the Netherlands.

Ronald van Dam (R)

Department of Surgery, Maastricht University Medical Center, Maastricht, the Netherlands.
Department of General, Visceral and Transplant Surgery, University Hospital Aachen, Germany.

Martijn W J Stommel (MWJ)

Department of Surgery, Radboud University Medical Center, Nijmegen, the Netherlands.

Kees van Laarhoven (K)

Department of Surgery, Radboud University Medical Center, Nijmegen, the Netherlands.

Roeland F de Wilde (RF)

Department of Surgery, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.

Sebastiaan Festen (S)

Department of Surgery, OLVG Oost, Amsterdam, the Netherlands.

Werner A Draaisma (WA)

Department of Surgery, Jeroen Bosch Hospital, 's Hertogenbosch, the Netherlands.

Koop Bosscha (K)

Department of Surgery, Jeroen Bosch Hospital, 's Hertogenbosch, the Netherlands.

Casper H J van Eijck (CHJ)

Department of Surgery, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.

Olivier R Busch (OR)

Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands.
Cancer Center Amsterdam, Amsterdam, the Netherlands.

I Quintus Molenaar (IQ)

Department of Surgery, Regional Academic Cancer Center Utrecht, University Medical Center Utrecht and St. Antonius Hospital Nieuwegein, Utrecht University, the Netherlands.

Bas Groot Koerkamp (B)

Department of Surgery, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.

Hjalmar C van Santvoort (HC)

Department of Surgery, Regional Academic Cancer Center Utrecht, University Medical Center Utrecht and St. Antonius Hospital Nieuwegein, Utrecht University, the Netherlands.

Marc G Besselink (MG)

Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands.
Cancer Center Amsterdam, Amsterdam, the Netherlands.

Classifications MeSH